GLP-1 Pipeline 2026

Why this article exists

The receptor map of metabolic medicine fully bifurcated in 2025-2026. Where the entire space ran on one molecule (semaglutide) and one receptor (GLP-1) for years, by mid-2026 there are fourteen agents at various stages of approval and Phase 3 readout, hitting four receptor families (GLP-1, GIP, glucagon, amylin) in eight different combinations:

• GLP-1 single agonist: Semaglutide, Liraglutide, Dulaglutide.
• GLP-1 + GIP dual agonist: Tirzepatide, VK2735 (oral + subq).
• GLP-1 agonist + GIP antagonist: MariTide — the one combination that runs GIP the opposite direction and still produces ~20% weight loss (the live mechanistic paradox of the class).
• GLP-1 + glucagon dual agonist: Survodutide, Mazdutide, Pemvidutide.
• GLP-1 + amylin combo: CagriSema.
• Selective amylin only: Eloralintide, Petrelintide.
• Oral small-molecule GLP-1: Orforglipron (Foundayo).
• GLP-1 + GIP + glucagon triple agonist: Retatrutide.

This article is the map. It positions where Retatrutide (Alyve’s flagship metabolic SKU) sits in the broader pipeline (the most-potent triple-agonist end), explains the mechanism progression, and covers the eight drugs around it — what each one does, what trials have read out, and where each one is headed.

Alyve availability: Of the nine drugs covered here, Retatrutide is in Alyve’s catalog (10 mg / 20 mg, COA 99.01% / 99.13%). Semaglutide and tirzepatide are widely available via 503A compounding (Alyve-adjacent supply). The rest are FDA-approved branded products or pipeline candidates and sit outside Alyve’s verified-vendor lane — but understanding where they are matters for the buyer trying to decide between “start verified-compounded Reta today” vs. “wait for Foundayo / CagriSema in 2026-2027.” That choice is the practical commercial pivot of this whole landscape article.

---

The big picture — three takeaways before the table

1. The receptor map has bifurcated. The “GLP-1 era” is now a four-receptor era: GLP-1, GIP, glucagon, amylin. The next few years of obesity medicine are about combinations of those four — and Reta is the first molecule to hit three of them at once.
2. Tirzepatide is still the weight-loss-efficacy benchmark to beat. CagriSema 2.4/2.4 mg head-to-head vs. Tirzepatide 15 mg in REDEFINE-4 missed non-inferiority at 84 weeks. Mazdutide 9 mg (20.1%), Survodutide (16.6%), and Eloralintide (20%) cluster below or near Tirzepatide. Retatrutide-class triple agonists likely retain the absolute-efficacy crown.
3. Three Phase-3-winning new entrants in late 2025 / early 2026 changed the landscape: Orforglipron (oral small-molecule GLP-1; NEJM ATTAIN-1 published; brand name “Foundayo”), CagriSema (FDA NDA filed Dec 2025; decision expected Q4 2026), and Mazdutide (first-in-class dual GCG/GLP-1 approved anywhere — China NMPA 2025-2026; Nature back-to-back Phase 3 papers).

---

The landscape at a glance

Drug	Agonism	Sponsor	Best wt-loss reported	Latest milestone	Brand	Route
Liraglutide	GLP-1 (single, daily)	Novo Nordisk	~5–9%	FDA approved 2010 (T2D) / 2014 (obesity)	Victoza / Saxenda	SubQ daily
Dulaglutide	GLP-1 (single, weekly)	Lilly	~4.7 kg (4.5 mg, 36 wk, AWARD-11)	FDA approved (T2D 2014; +3.0/4.5 mg 2020); not approved for obesity	Trulicity	SubQ weekly
Semaglutide	GLP-1 (single, weekly)	Novo Nordisk	~15% (STEP-1)	FDA approved (T2D 2017, obesity 2021)	Ozempic / Wegovy / Rybelsus	SubQ weekly + oral daily
Tirzepatide	GLP-1 + GIP (dual)	Lilly	~20.9% (SURMOUNT-1)	FDA approved (T2D May 2022, obesity Nov 2023)	Mounjaro / Zepbound	SubQ weekly
CagriSema	GLP-1 + amylin (combo)	Novo Nordisk	22.7% (REDEFINE); 12.9% vs. 9.2% Sema head-to-head; MISSED non-inferiority vs. Tirz 15 mg in REDEFINE-4	NDA filed Dec 2025; Q4 2026 FDA decision	TBD	SubQ weekly
Mazdutide	GLP-1 + glucagon (dual)	Innovent (Lilly China license)	20.1% (GLORY-2, 9 mg)	China NMPA approved 2025-2026: first-in-class for the GCG/GLP-1 dual class anywhere	TBD	SubQ weekly
Orforglipron	Oral small-molecule GLP-1	Lilly	9.2% (ACHIEVE-3, 36 mg); higher in ATTAIN-1	NEJM ATTAIN-1 published 2026	Foundayo	Oral daily, no food/water restrictions
Survodutide	GLP-1 + glucagon (dual)	Boehringer + Zealand	16.6% (SYNCHRONIZE-1) + 63.1% liver fat reduction	Phase 3 SYNCHRONIZE-1 reported 2026; FDA Breakthrough Therapy for MASH	TBD	SubQ weekly
Eloralintide	Selective amylin only (no GLP-1)	Lilly	20.1% (Phase 2, 9 mg, 48 wks)	Phase 2 done Nov 2025 (Lancet); Phase 3 expected late 2026	TBD	SubQ weekly
MariTide (maridebart cafraglutide)	GLP-1 agonist + GIP antagonist (peptide–antibody conjugate)	Amgen	~20% (52 wk, obesity); ~17% w/ T2D	Phase 2 NEJM 2025 (PMID 40549887); Phase 3 MARITIME	TBD	SubQ once-MONTHLY
Pemvidutide	GLP-1 + glucagon (dual)	Altimmune	15.6% (2.4 mg, 48 wk, MOMENTUM)	Obesity + MASH Phase 2b done; → Phase 3. MASH resolution 59% @24wk (IMPACT, Lancet 2025)	TBD	SubQ weekly
Petrelintide	Selective amylin only	Zealand / Roche	10.7% (42 wk, ZUPREME-1)	Phase 2b positive (Mar 2026); Phase 3 H2-2026	TBD	SubQ weekly
VK2735	GLP-1 + GIP (dual)	Viking	14.7% subq / 12.2% oral (13 wk)	Phase 3 (VANQUISH subq); oral → Phase 3	TBD	Oral daily + SubQ weekly
Retatrutide	GLP-1 + GIP + glucagon (triple)	Lilly	~24.2% (Phase 2, 12 mg, 48 wks); −28.3% TRIUMPH-1 Phase 3 topline	Phase 3 TRIUMPH reading out positive	TBD	SubQ weekly

All weight-loss numbers above are corporate-reported / press-release / topline figures — against the primary publications (NEJM ATTAIN-1, Lancet ACHIEVE-3, Lancet Eloralintide Phase 2, Nature back-to-back Mazdutide papers, NEJM SURMOUNT-1, NEJM Phase 2 Retatrutide PMID 37366315) before any customer-facing use. Corporate press releases consistently spin to the best-dose / best-population subgroup — never quote a single percentage without the dose + duration + population context this table provides.

---

The four receptor families — what they do

• GLP-1 (glucagon-like peptide-1). Stimulates glucose-dependent insulin secretion in the pancreas; slows gastric emptying (food sits longer, satiety hits sooner); centrally suppresses appetite via hypothalamic GLP-1 receptors. The foundational obesity-drug receptor.
• GIP (glucose-dependent insulinotropic polypeptide). Synergistic with GLP-1: augments insulin secretion further and modulates lipid metabolism in adipocytes. Tirzepatide was the first molecule to add this — and added ~6 percentage points of weight loss over Wegovy.
• Glucagon (the third receptor: the new lever). Glucagon agonism in the liver and brown fat raises resting energy expenditure and drives fat oxidation rather than just suppressing intake. Your body burns more, not only eats less. Normally glucagon would raise blood sugar; in dual or triple combinations, the GLP-1 + GIP arms keep insulin robust, so the fat-burning effect runs largely unopposed. This is the mechanism that breaks the plateau on pure GLP-1 drugs. Survodutide, Mazdutide, and Retatrutide are the glucagon-receptor players.
• Amylin. The pancreatic hormone naturally co-secreted with insulin. Drives satiety and slows gastric emptying via the amylin-specific receptor — a separate, parallel pathway to GLP-1, not a subordinate one. Cagrilintide (in CagriSema) and Eloralintide (selective amylin only) prove the amylin pathway alone delivers GLP-1-class efficacy with what appears to be a lighter GI burden.

---

Per-drug snapshots

Liraglutide (Saxenda / Victoza)

The foundational chapter. Victoza was FDA-approved 2010 for T2D at 1.8 mg/day; Saxenda was FDA-approved December 2014 for obesity at 3.0 mg/day — the first GLP-1 specifically approved for weight management, nearly seven years before Wegovy. Same molecule, two doses, two indications.

• Mechanism: standard GLP-1R agonist; the prototype.
• Efficacy: 5.7–9.2% weight loss (6.0–8.8 kg) across obesity trials; 62% lost ≥5% at 1 year (vs. 34% placebo).
• The daily-dose disadvantage: once-daily injection is a real compliance hit vs. weekly competitors. Market share has declined sharply since 2021 as patients migrated to weekly semaglutide and tirzepatide.
• Status: FDA-approved; widely available; commercially being squeezed by weekly options.

Semaglutide (Ozempic / Wegovy / Rybelsus)

The drug that defined the era. Weekly subcutaneous (Ozempic for T2D, Wegovy for obesity) and a daily oral version with strict fasting requirements (Rybelsus). STEP-1 trial: ~15% mean weight loss at 68 weeks. Widely available in 503A compounded form for the cash-pay market.

• Mechanism: GLP-1R agonist; longer half-life than liraglutide (weekly vs. daily).
• Why it matters as a reference point: every newer drug is benchmarked against semaglutide’s ~15% as the prior leader.
• Status: FDA-approved; verified-compounded versions are part of the Alyve-adjacent supply landscape.

Dulaglutide (Trulicity — Lilly)

The legacy weekly GLP-1 — the drug that proved “once-weekly GLP-1” worked, before semaglutide raised the ceiling. Once-weekly subcutaneous GLP-1 receptor agonist, FDA-approved for type 2 diabetes (2014) and cardiovascular risk reduction (the REWIND CV-outcomes trial). Doses 0.75 → 4.5 mg/week, titrated over 4–8 weeks.

• Mechanism: standard GLP-1R agonist; strong glycemic + cardiovascular drug, weak weight drug.
• Weight effect (AWARD-11, 36 wk): ~4.7 kg (4.5 mg), ~4 kg (3 mg), ~3 kg (1.5 mg): i.e. ~2–4 kg secondary weight loss, far below sema/tirz/reta. Not FDA-approved for obesity.
• Why it’s in the landscape: it’s the reference point for “first-generation weekly GLP-1” and shows how far the class has moved in a decade. It was also the active comparator in retatrutide’s Phase 2 T2D trial (Rosenstock 2023 Lancet) — see Retatrutide.

Tirzepatide (Mounjaro / Zepbound) — own article

Dual GLP-1 + GIP. SURMOUNT-1 (Phase 3, n=2,539, 72 wks): 5 mg = 15%, 10 mg = 19%, 15 mg = 20.9% weight loss vs. 3% placebo. FDA-approved for T2D (May 2022) and obesity (Nov 2023, branded Zepbound). Full breakdown in Tirzepatide.

• Why it’s still the benchmark: CagriSema’s REDEFINE-4 head-to-head failed non-inferiority at 84 weeks; no dual-or-lesser-agonist on the market or in Phase 3 has cleanly beaten Tirz 15 mg yet.
• Where it sits in this landscape: the dual-agonist crown until a Retatrutide-class triple agonist gets FDA approval.

CagriSema (cagrilintide + semaglutide — Novo Nordisk)

Fixed-dose combination 2.4 mg cagrilintide (long-acting amylin analog) + 2.4 mg semaglutide in a single weekly SubQ injection — the first once-weekly GLP-1 + amylin combination. FDA NDA filed December 2025; decision expected Q4 2026.

• The wins: 22.7% weight loss in a Phase 3 obesity trial; 12.9% vs. 9.2% head-to-head against semaglutide 2.4 mg alone at 68 weeks (beats sema).
• The critical loss: REDEFINE-4 head-to-head vs. tirzepatide 15 mg at 84 weeks did not meet non-inferiority on weight loss. Tirzepatide retains the dual-agonist efficacy crown.
• Commercial position: “beats semaglutide alone but doesn’t beat tirzepatide” — a narrower commercial wedge than Novo hoped for, but still a real product if approved.

Mazdutide (Innovent + Lilly China license)

First-in-class dual GCG/GLP-1 receptor agonist approved anywhere in the world — China NMPA approved for chronic weight management in 2025-2026. Mammalian oxyntomodulin (OXM) analogue — leverages the natural OXM peptide’s dual receptor activity. Two Phase 3 mazdutide papers published back-to-back in Nature 2026 on T2D outcomes in Chinese adults — peer-reviewed validation.

• Efficacy: GLORY-2 (Chinese adults with obesity): 9 mg → 20.1% weight loss at primary endpoint. GLORY-1 (48 wks): 12.0% (4 mg) / 14.8% (6 mg) vs. 0.5% placebo.
• Why the mechanism matters here: glucagon-receptor activation increases energy expenditure and improves hepatic fat metabolism — distinct from GLP-1-only agents that work primarily through appetite + insulin signaling.
• Status: China-only approval initially, but it validates the GCG/GLP-1 dual class globally — Lilly’s licensing relationship makes Mazdutide a Lilly-globalization asset alongside Mounjaro/Zepbound, Foundayo, and Retatrutide.

Orforglipron (Foundayo — Lilly)

Oral small-molecule GLP-1 receptor agonist — not a peptide. A synthetic small molecule that hits the GLP-1 receptor with no food or water timing restrictions (the constraint that has kept oral semaglutide / Rybelsus from breaking through). Brand name Foundayo.

• Why this matters: the first credible “GLP-1 in a pill.” The substantial patient population that won’t inject finally has a credible oral option.
• Efficacy (ACHIEVE-3, n=1,698, 52 wks): orforglipron 36 mg = −19.7 lbs (9.2%); 12 mg = −14.6 lbs (6.7%). Oral semaglutide 14 mg = −11.0 lbs (5.3%); 7 mg = −7.9 lbs (3.7%). Orforglipron outperformed oral semaglutide across primary and all key secondary endpoints (A1C + weight).
• Status: NEJM ATTAIN-1 (obesity Phase 3, Wharton et al. 2025, n=3,127, 72 wk; 36 mg −11.2% body weight) — PMID 40960239; Lancet ACHIEVE-3 (T2D, head-to-head vs oral semaglutide, Rosenstock et al. 2026, n=1,698, 52 wk) — PMID 41765029. ACHIEVE program (T2D) Phase 3 met primary + key secondary endpoints across multiple trials with 6,000+ enrolled. Regulatory submissions for obesity expected to follow ATTAIN-1; likely 2026-2027 global filings. See Orforglipron for the full standalone breakdown.
• Commercial position: competes directly with Wegovy + Zepbound for the daily-pill-preference cohort.

Survodutide (Boehringer Ingelheim + Zealand Pharma)

Glucagon + GLP-1 dual receptor agonist — same class as Mazdutide but a distinct molecule. Discovered + initially developed by Zealand, licensed to Boehringer for global development. FDA Breakthrough Therapy designation for MASH (metabolic dysfunction-associated steatohepatitis) — separate development track from obesity.

• Efficacy in obesity (SYNCHRONIZE-1, 76 wks): 16.6% mean weight loss (up to 17.8 kg / 39.2 lbs at highest dose). Below tirzepatide on weight loss alone.
• The standout result (SYNCHRONIZE-1 body-comp sub-study, June 2026): 34% visceral fat reduction + 63.1% liver fat reduction at 76 weeks — the highest reported liver-fat reduction in the entire GLP-1 obesity-pipeline class. Lean-mass loss limited to ≤10.8% of total tissue change at the highest dose — better lean-mass preservation than expected.
• Why the mechanism matters here: the glucagon arm drives fatty-acid oxidation directly in the liver. That’s what makes Survodutide a MASH play, not an obesity-only play. MASH is a large untreated market with no FDA-approved drugs to date.
• Status: Phase 3 SYNCHRONIZE program reported 2026; LIVERAGE program (MASH/fibrosis) is the FDA Breakthrough Therapy lane.

Eloralintide (Lilly)

Selective amylin receptor agonist: no GLP-1 activity at all. The amylin-only pathway player, proving the amylin pathway alone delivers GLP-1-class efficacy.

• Efficacy (Phase 2, Lancet 2025, n=263, 48 wks): mean weight reductions 9.5% to 20.1% across dose tiers vs. 0.4% placebo. Maximum mean reduction: 20% (−21.3 kg). 80% of the 9 mg dose group improved ≥1 BMI category. All treatment arms met the primary endpoint.
• The standout finding (tolerability): mild-to-moderate GI symptoms most common — incidence similar to placebo in lower dose arms. Amylin pathway appears to have a lighter GI burden than GLP-1 pathway at equivalent efficacy doses.
• Editorial implication: Eloralintide breaks the GLP-1 monopoly thesis. The amylin pathway is a legitimate parallel to GLP-1, not subordinate. The next generation of obesity drugs may stack amylin agonists with GLP-1 agonists in combinations beyond what CagriSema already does.
• Status: Phase 2 complete (November 2025); Phase 3 expected late 2026.

MariTide (maridebart cafraglutide — Amgen)

The structural outlier of the class: not a peptide and not a small molecule but a peptide–antibody conjugate, engineered for a once-MONTHLY subcutaneous shot: the standout convenience play in a field of weekly (or daily) drugs. And it runs the receptors in an unusual direction: GLP-1 receptor agonist + GIP receptor antagonist.

• The mechanistic paradox (great content angle): tirzepatide is a GIP agonist; MariTide is a GIP antagonist — and both produce ~20% weight loss. That two opposite GIP directions both “work” is one of the genuinely unresolved debates in incretin science. Surface it; don’t pretend it’s settled.
• Efficacy (Phase 2, NEJM 2025, PMID 40549887): obesity without T2D: mean weight loss up to ~20% at 52 weeks (12.3–16.2% across groups, no clear plateau); obesity with T2D — up to ~17% plus HbA1c reduction up to −2.2%.
• Safety: GI-led (nausea, vomiting, constipation), class-typical; titration matters.
• Status: Phase 3 MARITIME program underway; not FDA-approved.

Pemvidutide (Altimmune)

GLP-1 + glucagon dual agonist (same family as Survodutide/Mazdutide, distinct molecule) with a dual obesity + MASH development story — the glucagon arm drives hepatic fat oxidation.

• Obesity (MOMENTUM Phase 2, n=391, 48 wk): 10.3% / 11.2% / 15.6% at 1.2 / 1.8 / 2.4 mg vs 2.2% placebo; >30% of the top-dose group lost ≥20%; weight still trending down at week 48. Notable: lipid/BP gains without a clinically meaningful heart-rate rise.
• MASH (IMPACT Phase 2b; Lancet 2025 + AASLD 2025): MASH resolution 59.1% / 52.1% vs 19.1% placebo at 24 wk (first candidate to hit significant MASH resolution and weight loss at 24 wk); 48-wk liver fat −45.2% / −54.7% vs −8.2%, with significant noninvasive fibrosis-marker improvement (ELF, LSM). FDA End-of-Phase-2 supports registrational Phase 3.
• Status: advancing to Phase 3 (obesity + MASH); not FDA-approved.

Petrelintide (Zealand Pharma / Roche)

A long-acting selective amylin analog (amylin monotherapy, the same emerging class as Eloralintide): and the amylin class’s central pitch is tolerability, not just efficacy.

• Efficacy (Phase 2b ZUPREME-1, n=493, mean BMI 37; topline Mar 2026): up to 10.7% mean weight loss at week 42 vs 1.7% placebo; primary endpoint met in all five arms at 28 wk.
• The story is the safety: “placebo-like” tolerability: at the maximally effective dose, no vomiting and no GI-related discontinuations. If amylin-class drugs deliver GLP-1-class results without the GLP-1 GI burden, that reshapes who can tolerate treatment.
• Status: Roche–Zealand co-development (2025). Phase 3 chronic-weight-management start H2 2026; ZUPREME-2 (overweight/obese + T2D) topline H2 2026.

VK2735 (Viking Therapeutics)

A GLP-1 + GIP dual agonist (same receptor pair as tirzepatide) developed in both an oral tablet and a weekly subcutaneous formulation — Viking is racing to field the first oral GLP-1/GIP dual.

• Oral (Phase 2 VENTURE-Oral, 13 wk): up to 12.2% from baseline (10.9% placebo-adjusted), most AEs mild/moderate.
• Subcutaneous (Phase 2 VENTURE, 13 wk): up to 14.7% weight loss; met primary + all secondary endpoints.
• Status: SubQ in Phase 3 (VANQUISH-1 / VANQUISH-2); oral advancing to Phase 3. Not FDA-approved. If the oral reaches market first, it’s the first oral dual agonist — a different bet than orforglipron’s oral single GLP-1.

Retatrutide (Lilly) — own article

GLP-1 + GIP + glucagon triple agonist — the first molecule to hit all three. Alyve’s flagship metabolic SKU.

• Efficacy: Phase 2 (Jastreboff/NEJM 2023, PMID 37366315) — −24.2% at 48 wks (12 mg), the largest non-surgical weight loss ever recorded for a pharmacological agent. Phase 3 TRIUMPH topline: TRIUMPH-1 −28.3% at 80 wks (12 mg), with a BMI≥35 extension reaching −30.3% at 104 wks; TRIUMPH-4 −28.7% at 68 wks.
• Phase 2 MASLD trial (Sanyal/Nature Medicine 2024): up to −86% liver fat at 48 wks (12 mg) — beats Survodutide’s 63.1% in cross-trial comparison.
• Where it sits in this landscape: the absolute-efficacy end. Until a competitor reaches Retatrutide-class triple agonism with a clean safety profile, Retatrutide holds the most-potent crown.
• Full breakdown: Retatrutide (the wiki article).

---

The mechanism progression — Sema → Tirz → Reta in one breath

Semaglutide = GLP-1 alone → suppress appetite + glucose ~15% wt loss
Tirzepatide = GLP-1 + GIP → + insulin synergy + fat handling ~20.9% wt loss
Retatrutide = GLP-1 + GIP + Glucagon → + raised energy expenditure ~24-28%+ wt loss

Each step adds a receptor; each receptor adds a mechanism; each mechanism adds a few percentage points of weight loss and (importantly) one additional axis of metabolic improvement. Survodutide and Mazdutide hit GLP-1 + Glucagon but skip GIP — that’s the reason their weight-loss numbers cluster below Tirzepatide on obesity-alone metrics even though their liver-fat numbers are excellent.

CagriSema and Eloralintide bring amylin into the picture as a fourth axis — a parallel pathway, not just a stack on top of GLP-1. The next round of pipeline candidates will likely combine amylin with GLP-1 + GIP + glucagon, but the molecules aren’t public yet.

Side-effect profile — the class baseline

All GLP-1 agents share a core AE profile:

• GI dominant: nausea, vomiting, diarrhea, constipation — worst during titration, mostly mild to moderate, attenuates over 4–8 weeks.
• Discontinuation rates typically ~5–10% across Phase 3 obesity trials.
• Boxed warning class-wide: thyroid C-cell tumors observed in rodent studies → contraindicated in personal/family history of medullary thyroid carcinoma or MEN-2 syndrome.
• Pancreatitis + gallbladder disease: monitored across all programs; not statistically elevated vs. placebo in well-powered trials.

Variations:

• Glucagon-receptor agents (Survodutide, Mazdutide, Retatrutide): glucagon component raises a theoretical hyperglycemia concern; closely monitored in T2D trials; β-hydroxybutyrate rise (fat-burning fingerprint) without ketoacidosis is the typical pattern.
• Amylin agents (CagriSema, Eloralintide): lighter GI burden at equivalent efficacy doses — the standout tolerability signal of the class.
• Lean-mass loss: roughly 25% of total weight lost can be lean mass without resistance training + protein. Survodutide’s body-comp sub-study reported better lean-mass preservation than expected (≤10.8% of tissue change at the highest dose). The Tyna Moore Tirzepatide digest reports 75–80% fat / 20–25% lean preservation. Either way: resistance training + adequate protein during a GLP-1 cycle is non-negotiable if you want the weight you lose to be fat.

Where experts disagree

• Compounded GLP-1 supply quality. The conservative-medicine read (per Tyna Moore’s compounding-pharmacist friend, paraphrased): “stick to brand name; nobody knows what’s in the unverified compounding-ies.” The verified-compounding read (per Chris Neal on HCG and the broader supply-chain literature): verified compounders with third-party COAs make products clinically equivalent to brand-name; the “compounded is scary” framing collapses verified and unverified into one category. Both are right about different categories. Alyve’s third-party Freedom Diagnostics COA model is the answer to the specific quality concern.
• Microdosing as a weight-loss strategy. The a popular practitioner GLP-1 masterclass framing: microdosing is a hormone-balance + longevity strategy, not a fat-loss strategy. Standard starting doses (Sema 0.25 mg/wk, Tirz 2.5 mg/wk) are not “microdoses” — and telemedicine affiliates pushing standard starting doses as “microdose protocols” are mislabeling for marketing reasons. The microdose protocol is real but its use case is metabolic optimization, not aggressive weight loss.
• Tirzepatide vs. CagriSema for the “next mainstream” position. REDEFINE-4 settled the head-to-head efficacy question. The Novo Nordisk read: CagriSema still wins commercially because of the once-weekly amylin + GLP-1 combination format and lighter GI burden. The Lilly read: Tirzepatide retains the efficacy crown and Foundayo + Retatrutide cover the oral and triple-agonist lanes. The buyer’s read: depends on whether they prioritize maximum weight loss (Tirz / Reta), tolerability (amylin-component agents), or pill-format (Foundayo).
• Glucagon-receptor activation as a real differentiator vs. a marketing story. Survodutide’s 63.1% liver-fat reduction and Retatrutide’s −86% liver-fat reduction are the strongest evidence that the glucagon arm produces qualitatively different downstream effects (direct hepatic fatty-acid oxidation), not just incremental weight loss. The skeptical read is that more weight loss → more liver fat loss as a byproduct. The mechanism read is that glucagon agonism produces direct effects on the liver independent of total weight loss. Both can be partially true; the cross-trial comparison favors the mechanism read.

How to think about timing — "start now" vs. "wait for Foundayo / CagriSema"

This is the practical decision the buyer is making, and it’s the conversion-relevant question. The honest framing:

• Start now (verified-compounded supply via Alyve): immediate access to Retatrutide (the most-potent triple agonist in the entire landscape; Alyve carries it at 10 mg / 20 mg with COAs at 99.01% / 99.13%). Faster results; lower per-month cost than brand-name; the verified-supply story (Freedom Diagnostics COA, US manufacturing, >99% purity) handles the legitimate quality concern about compounded GLP-1 supply.
• Wait for Foundayo / CagriSema / future approvals: branded FDA-approved supply; possible insurance coverage; daily oral format (Foundayo) for the injection-averse. Trade-off: 12–24 months until your buying decision actually starts working, plus brand-name out-of-pocket costs that run $1000+/month even when insured.

Neither is wrong. The frame that helps the reader: if you’re trying to fix something now, the molecule already exists and the verified supply already exists. If you’re trying to avoid injecting, Foundayo is the credible oral path — but it’s still 12–24 months out for obesity indications.

The Alyve product (commercial layer)

Retatrutide is in Alyve’s catalog. The triple agonist that sits at the top of this entire landscape on absolute efficacy is the one Alyve already stocks — Retatrutide 10 mg ($104) and 20 mg ($164), Freedom Diagnostics COA at 99.01% and 99.13% purity. This is the Alyve flagship in metabolic medicine, and this article exists in part to position where it sits in the broader pipeline (most-potent triple-agonist end).

Tirzepatide and semaglutide are widely available via 503A compounding (the Alyve-adjacent supply landscape); see Tirzepatide for the Tirz-specific framing. The remaining six drugs in this article are FDA-approved branded products or pipeline candidates — outside the Alyve verified-vendor lane.

The trust story. Independent gray-market peptide testing has consistently found roughly 1 in 4 vials underdosed, mislabeled, or contaminated. That’s the specific quality concern the “stick to brand name” framing exists to address — and Alyve answers it directly with US manufacturing + third-party Freedom Diagnostics COAs + verified >99% purity across the catalog. Verified compounded ≠ unverified compounded. The COA is the proof.

Use code OHM-15 for 15% off: Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. The practical bulk-stack play for this landscape’s audience is 3 vials of Retatrutide for a full extended titration / metabolic-restoration cycle.

Sources

• the source digest covering Liraglutide, CagriSema, Mazdutide, Orforglipron, Survodutide, Eloralintide with primary literature anchors.
• the foundational class-level mechanism + cycling + microdose framework.
• the Tirzepatide source pair (full breakdown in Tirzepatide).
• Retatrutide SKUs + COAs.
• Primary literature anchors: NEJM ATTAIN-1 (Orforglipron obesity, Wharton 2025) — PMID 40960239 ✓; Lancet ACHIEVE-3 (Orforglipron T2D head-to-head, Rosenstock 2026) — PMID 41765029 ✓; SURMOUNT-1 Tirzepatide (Jastreboff NEJM 2022) — PMID 35658024 ✓; STEP-1 Semaglutide (Wilding NEJM 2021) — PMID 33567185 ✓; Jastreboff/NEJM 2023 Phase 2 Retatrutide — PMID 37366315 ✓; Sanyal/Nature Medicine 2024 Retatrutide MASLD — PMID 38858523 (PMC11271400) ✓. Still: Lancet Eloralintide Phase 2 (n=263, 48 wks); Nature back-to-back Mazdutide Phase 3 T2D papers; Boehringer SYNCHRONIZE-1 (Survodutide); Novo Nordisk REDEFINE program (CagriSema).

Related: Retatrutide · Tirzepatide · MOTS-c · NAD+ · CJC-1295 / Ipamorelin (muscle-preservation adjuvant during any GLP-1 cycle).